Daicel (4202) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
17 Jun, 2026Executive summary
Net sales for Q1 FY2025/3 reached ¥145.6 billion, up 11.3% year-over-year, driven by recovery in electronic materials and engineering plastics demand, cost reductions, and favorable exchange rates.
Operating income surged 91.5% year-over-year to ¥17.5 billion, with net income attributable to owners up 8.0% to ¥16.2 billion.
Both net sales and operating income exceeded forecasts due to stronger-than-expected demand recovery and yen depreciation, despite negative impacts from a certification misconduct issue at a Japanese automobile manufacturer.
Comprehensive income reached ¥33,957 million, up 9.8% year-over-year.
Financial highlights
EBITDA rose to ¥27.0 billion, up 62.7% year-over-year.
Ordinary income increased 43.2% year-over-year to ¥18.2 billion.
EPS for Q1 FY2025 was ¥58.70, up from ¥52.46 in Q1 FY2024.
Total assets as of June 30, 2024, were ¥869.5 billion, up ¥30.3 billion from March 31, 2024.
Net assets increased to ¥402.4 billion, with a capital adequacy ratio of 44.3%.
Outlook and guidance
FY2025/3 full-year net sales forecast is ¥610.0 billion, up ¥51.9 billion from the previous year.
Operating income forecast is ¥65.0 billion, ordinary profit at ¥67.0 billion, and net income at ¥58.0 billion.
Annual dividend forecast is ¥55 per share, up ¥5 from the previous year, with a DOE target of 4.0%.
No revision to forecasts since May 9, 2024.
Latest events from Daicel
- Operating income fell 25% year-over-year, but healthcare and mobility segments grew.4202
Q1 202617 Jun 2026 - Strong 1H growth driven by plastics and Smart segment, but full-year net income guidance cut.4202
Q2 202517 Jun 2026 - Sales and profits fell on FX and global headwinds, but cost controls lifted select segment margins.4202
Q2 202617 Jun 2026 - Sales rose 5.1%, but profits declined; FY2026 outlook: higher sales, lower profits, stable dividends.4202
Q4 202517 Jun 2026 - Net sales up 4.4% year-over-year, but profit margins declined amid mixed segment results.4202
Q3 202517 Jun 2026 - Profits fell on lower sales, but healthcare and safety segments showed strong growth.4202
Q3 202617 Jun 2026 - Profits fell on impairment losses, but FY2027 net income is forecast to rebound strongly.4202
Q4 202617 Jun 2026